Company Overview
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Why Investors Should Care
Revenue has grown at a 49.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $40.93M (+25.7% YoY); net profit $-15.57M.
- Trailing 12 Months Year-on-year growth — revenue +2.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 49.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 49.41% |
| 1 Year: | 2.90% |
Stock Price Performance
| 1 Year: | +37.14% |
| 6 Months: | +79.78% |
| 3 Months: | +12.50% |
| 1 Month: | +9.92% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)50.41 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 49.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MYO Myomo, Inc. R2KPHARMA | 1.44 | -4.24 | $57.04M | 0.00% | -47.54% | -98.53% | 49.41% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 313.18K | 632.37K | 608.98K | 830.07K | 880.35K | 606.62K | 1.01M | 858.59K | 1.93M | 2.34M | 3.10M | 4.38M | 3.87M | 3.68M | 3.97M | 3.45M | 5.96M | 5.08M | 3.75M | 7.52M | 9.21M | - | 9.83M | 9.65M | 10.09M | 11.35M | 10.11M | 11.70M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.22M | 3.60M | 3.65M | 3.57M | 3.21M | - |
| Gross Profit | 203.88K | 107.11K | 137.66K | 208.04K | 364.44K | 205.10K | 431.92K | 415.40K | 543.26K | 500.26K | 277.39K | 689.49K | 439.73K | 1.07M | 1.71M | 2.20M | 3.27M | 2.58M | 2.40M | 2.64M | 2.31M | 4.28M | 3.49M | 2.30M | 5.33M | 6.95M | - | 6.61M | 6.05M | 6.44M | 7.78M | 6.90M | 8.44M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.13M | 10.64M | 9.96M | 10.56M | 10.06M | - |
| Operating Income | -688.58K | -933.83K | -1.36M | -1.93M | -1.43M | -2.40M | -2.68M | -2.71M | -2.68M | -2.71M | -2.83M | -3.42M | -2.85M | -2.55M | -2.93M | -2.60M | -2.03M | -2.74M | -2.90M | -2.82M | -2.67M | -1.10M | -2.02M | -3.89M | -1.12M | -957.55K | - | -3.52M | -4.59M | -3.52M | -2.77M | -3.16M | -2.25M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.07M | -4.16M | -3.08M | -2.32M | -2.69M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.33M | -4.48M | -3.53M | -3.73M | -2.82M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 136.79K | 148.20K | 135.66K | 83.88K | 186.72K | - |
| Net Income | -759.89K | -1.02M | -1.56M | -7.38M | -1.26M | -2.35M | -2.63M | -2.65M | -2.60M | -2.57M | -2.79M | -3.80M | -3.29M | -2.78M | -2.96M | -2.62M | -2.06M | -2.81M | -2.91M | -2.83M | -2.64M | -1.01M | -2.03M | -3.84M | -1.12M | -966.41K | - | -3.47M | -4.63M | -3.66M | -3.81M | -3.01M | -4.02M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.46 | -0.36 | -0.41 | -0.42 | -0.40 | -0.11 | -0.04 | -0.06 | -0.10 | -0.03 | -0.03 | - | -0.08 | -0.11 | -0.09 | -0.09 | -0.07 | -0.09 |
| R&D Expense | 258.28K | 237.69K | 356.88K | 708.62K | 329.36K | 372.36K | 486.98K | 449.67K | 446.35K | 427.57K | 433.06K | 506.95K | 397.81K | 345.67K | 525.97K | 600.12K | 641.23K | 659.54K | 632.87K | 690.41K | 476.99K | 564.24K | 717.26K | 956.22K | 1.01M | 1.25M | - | 1.79M | 2.00M | 1.53M | - | 1.62M | 1.72M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.10M | 1.56M | 2.44M | 3.84M | 7.58M | 13.86M | 15.56M | 19.24M | 32.55M | 40.93M |
| Gross Profit | 821.11K | 1.05M | 1.72M | 2.42M | 4.98M | 10.31M | 10.25M | 13.18M | 23.19M | 26.89M |
| Operating Income | -3.28M | -6.55M | -10.53M | -10.80M | -10.50M | -10.27M | -10.67M | -8.23M | -6.21M | -14.40M |
| Net Income | -3.62M | -12.10M | -10.32M | -10.71M | -11.56M | -10.37M | -10.72M | -8.15M | -6.18M | -15.57M |
| Diluted EPS | - | - | - | - | - | -1.89 | -1.52 | -0.28 | -0.16 | -0.37 |
| R&D Expense | 1.12M | 1.75M | 1.84M | 1.75M | 1.67M | 2.56M | 2.48M | 2.64M | 4.77M | 6.94M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 1.66M | 13.97M | 8.28M | 6.60M | 14.71M | 20.10M | 10.16M | 14.58M | 42.24M | 38.64M |
| Total Equity | -13.90M | -17.53M | 12.45M | 6.43M | 6.43M | 11.57M | 15.41M | 6.36M | 8.99M | 24.71M | 11.40M |
| Cash & Equivalents | 1.04M | 797.17K | 12.96M | 6.54M | 4.47M | 12.24M | 15.52M | 5.35M | 6.87M | 24.37M | 14.13M |
| Long Term Debt | - | - | - | - | 888.96K | - | - | - | - | 0 | 11.22M |
| Total Liabilities | - | 6.52M | 1.53M | 1.86M | 4.77M | 3.14M | 4.69M | 3.80M | 5.59M | 17.53M | 27.23M |
| Current Liabilities | - | 3.00M | 1.49M | 1.86M | 3.88M | 2.87M | 4.28M | 3.60M | 5.48M | 10.17M | 8.35M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -3.20M | -6.15M | -9.61M | -10.34M | -9.03M | -9.55M | -10.23M | -6.17M | -3.29M | -14.51M |
| Investing Cash Flow | -1.86K | -67.00K | -126.87K | -51.99K | -45.75K | -326.46K | -310.79K | -2.03M | 259.98K | -7.06M |
| Financing Cash Flow | 2.96M | 18.38M | 3.34M | 8.32M | 16.78M | 13.17M | 376.86K | 9.71M | 20.93M | 11.43M |
| Capital Expenditure | -1.86K | -67.00K | -126.87K | -51.99K | -45.75K | -326.46K | -111.79K | -145.82K | -1.36M | -1.74M |
| Free Cash Flow | -3.20M | -6.22M | -9.73M | -10.39M | -9.08M | -9.87M | -10.35M | -6.32M | -4.65M | -16.25M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 74.4% | 67.6% | 70.2% | 63.0% | 65.7% | 74.4% | 65.9% | 68.5% | 71.2% | 65.7% |
| Operating Margin % | -296.8% | -420.1% | -430.8% | -281.3% | -138.5% | -74.1% | -68.6% | -42.8% | -19.1% | -35.2% |
| Net Margin % | -327.8% | -776.0% | -422.1% | -279.1% | -152.5% | -74.9% | -68.9% | -42.3% | -19.0% | -38.1% |
| ROE % | 20.6% | -97.2% | -160.5% | -166.7% | -100.0% | -67.3% | -168.6% | -90.6% | -25.0% | -136.6% |
| ROCE % | 243.8% | -52.4% | -163.8% | -397.6% | -88.7% | -64.9% | -162.7% | -90.4% | -19.4% | -47.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Rosalind Advisors, Inc. | 9.18% | 3.64M | $5.82M |
| 2 | Vanguard Capital Management LLC | 4.13% | 1.64M | $2.62M |
| 3 | AQR Capital Management, LLC | 2.34% | 928.27K | $1.49M |
| 4 | Jefferies Financial Group Inc. | 1.78% | 704.27K | $1.13M |
| 5 | Jane Street Group, LLC | 1.51% | 596.35K | $954.16K |
| 6 | Clearstead Advisors, LLC | 1.07% | 425.61K | $680.97K |
| 7 | UBS Group AG | 1.04% | 413.68K | $661.89K |
| 8 | Geode Capital Management, LLC | 0.87% | 344.42K | $551.07K |
| 9 | LPL Financial LLC | 0.78% | 308.00K | $492.80K |
| 10 | Palumbo Wealth Management Llc | 0.76% | 299.78K | $479.64K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MYO
A robotic arm device maker will present in New York Sept. 14-16 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxNaDhrWmtnV2RBd0c4eDFrRWdFQTZIR3l4WjF4dGpVWXpXeC12cXBoVXpteU5pUkFTUzk5X0s4VDZfZGFMUHE4QnFVOFI4NXMwOVlrTDFsZzhOUWZxUVRGaGJvYXpaTGFOTnpkOEROSkdZc0dvd1pvci1Sc1FidFBaME41Q2NkMDJIZ2hNRX…
Myomo (MYO) Shows Fast-paced Momentum But Is Still a Bargain Stock - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNODVUWXdJNkR1TERfTXRCTzBrXzVBOTM1T0JsbW1hWW9FNXJFMUJOOFB3S0dnSWdqWXVENk5OWHJuMXZrdGRSWnlMRFlCemtyWWJTdnFyMTNvM0I5XzhJaE5qdEMxbWt4dGRwWlFlbWdWWTc0WUhmTzdTRkZkeV9acnVxaWhXMFVFeV9tVT…
$MYO stock is down 18% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxPT3ZjcXFWMGY4NWItS21rTE5PcWZaMFJGNmxqc2NmRmtJMVNsWUswR2N2QVYtRzJiSl8yZDNkLXJ2aGpyd2JDU2V1NTBtbzU3WVRoWjVJZ3Zxem1XQzhLOUY5MmN1a0tXakFMdXhlV0dpMVdTYkRLdUZVZFhneUVEUFJab0h5RnNRclB6M2…
Director of Myomo (NYSE: MYO) moves to sell shares from recent stock awards - Stock Titan
<a href="https://news.google.com/rss/articles/CBMijgFBVV95cUxQQWNYY3BaTVZQcmNlU0Mza3hjOHp5ZE1abUoxVGpYSVVHVE9DSndMZHZRcXFJdFNteGM4dDRsY3V5d1o4NTJNSHBNTUVRV2d6MkxGTlNtM3dyb3RRZ2tuZmhXRVlfT3o0LURJTi0wQkVfOWZHQWx0SUpacGhqZEl1Ni0waW5sWGJ5eDdWQ2…
MYO - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE0tTTdhZXZxeE45ajJvWmZQRkxydGdLSTV2VEM0THJ0ZXZEMkFqeVdyR0U3YnpZZ19lUXJMOVNBUy1CTEZw?oc=5" target="_blank">MYO</a> <font color="#6f6f6f">Finviz</font>…
Myomo CMO Harry Kovelman sells $30,329 in stock By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxORHhVa2YwcmRUVlZtTHRWZGs5a1FOX2p0ZzdwNkxQdTh5QmJXa1RweDM0a0RidkFHZDFfZjFJOEVPSk9nblROOG5iVEVmeE5OU0NFOG5xaE02czlRejhGcXIwMTdpT1ktdXdKeDloUU90eG5vT1loQWlXMHZZXzNqd0FtQWlxb3c1S2NOOU…
MYO — Frequently Asked Questions
What is the current share price of Myomo, Inc. (MYO)?
As of 2026-09-07 16:24 PDT, Myomo, Inc. (MYO) trades at $1.44 on NYSE American. Its 52-week range is $0.64 to $1.86.
What is the market capitalisation of MYO?
Myomo, Inc. (MYO) has a market capitalisation of $57.04M on NYSE American.
What is the P/E ratio of MYO?
MYO trades at a trailing price-to-earnings (P/E) ratio of -4.24. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 6.09.
What is the return on equity (ROE) of MYO?
MYO has a return on equity (ROE) of -98.53%. Its return on capital employed (ROCE) is -47.54%.
Is MYO a good stock to buy?
This page provides a data-driven analysis of Myomo, Inc. (MYO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.